T. Rowe Price reports 7.5% stake in Kestra

T. Rowe Price Associates, Inc. filed a Schedule 13G reporting a significant passive ownership position in Kestra Medical Technologies common stock.

Rhea-AI Filing Summary

T. Rowe Price Associates, Inc. filed a Schedule 13G reporting a significant passive ownership position in Kestra Medical Technologies common stock. As of 12/31/2025, it reported beneficial ownership of 4,369,429 shares, representing 7.5% of the outstanding common stock.

The firm reports sole voting power over 4,208,056 shares and sole dispositive power over all 4,369,429 shares, with no shared voting or dispositive power. T. Rowe Price certifies the shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Kestra, and expressly denies beneficial ownership in a legal-admission sense.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does T. Rowe Price hold in Kestra Medical Technologies (KMTS)?

T. Rowe Price Associates reports beneficial ownership of 4,369,429 Kestra Medical Technologies common shares, representing 7.5% of the class as of 12/31/2025. This makes it a significant institutional shareholder under SEC ownership disclosure rules.

Does T. Rowe Price control Kestra Medical Technologies (KMTS) through this stake?

No. T. Rowe Price certifies the shares were acquired and are held in the ordinary course of business, not to change or influence control of Kestra. The filing is on Schedule 13G, which is used for passive, non‑control investment positions.

How much voting power does T. Rowe Price have in Kestra Medical (KMTS)?

T. Rowe Price reports sole voting power over 4,208,056 Kestra shares and no shared voting power. It also reports sole dispositive power over 4,369,429 shares, meaning it alone can decide how to vote most of the held shares.

When was T. Rowe Price’s 7.5% Kestra Medical (KMTS) stake measured?

The reported ownership is stated as of 12/31/2025, which is the date of the event requiring the Schedule 13G filing. The 7.5% figure reflects Kestra’s common stock outstanding at that time, as disclosed in the filing.

What type of SEC filing did T. Rowe Price submit for Kestra Medical (KMTS)?

T. Rowe Price filed a Schedule 13G, used by investors with more than 5% of a class of securities who qualify as passive holders. This contrasts with Schedule 13D, which is used when seeking to influence or change control.

Does T. Rowe Price admit full beneficial ownership of its Kestra (KMTS) shares?

No. T. Rowe Price declares that the filing should not be construed as an admission that it is the beneficial owner of the reported securities, and it expressly denies such beneficial ownership in a legal-admission sense.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/17/2026 - 10:26 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

KESTRA MEDICAL TECHNOLOGIES

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

G52441105

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. G52441105

1

Names of Reporting Persons

T. Rowe Price Associates, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MARYLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,208,056.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 4,369,429.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,369,429.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.5 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: KESTRA MEDICAL TECHNOLOGIES
(b)	Address of issuer's principal executive offices: 3933 LAKE WASHINGTON BLVD NE, SUITE 200, KIRKLAND, WA, 98033
Item 2.
(a)	Name of person filing: T. Rowe Price Associates, Inc.
(b)	Address or principal business office or, if none, residence: 1307 Point Street, Baltimore, MD 21231
(c)	Citizenship: Maryland
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: G52441105
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 4369429
(b)	Percent of class: 7.5 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 4208056
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 4369429
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

T. Rowe Price Associates, Inc.

Signature:	Ellen York
Name/Title:	Vice President
Date:	02/17/2026